Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study-Reference-Cited by-同舟云学术

Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study

Published:2016-10 Issue:2 Volume:1 Page:97-104
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Lau George,Benhamou Yves,Chen Guofeng,Li Jin,Shao Qing,Ji Dong,Li Fan,Li Bing,Liu Jialiang,Hou Jinlin,Sun Jian,Wang Cheng,Chen Jing,Wu Vanessa,Wong April,Wong Chris L P,Tsang Stella T Y,Wang Yudong,Bassit Leda,Tao Sijia,Jiang Yong,Hsiao Hui-Mien,Ke Ruian,Perelson Alan S,Schinazi Raymond F

Funder

Center for AIDS Research NIH grant

NIH

National Center for Research Resources and the Office of Research Infrastructure Programs

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference34 articles.

1. Hepatitis C guidance: AASLD–IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus;Hepatology,2015

2. EASL recommendations on treatment of hepatitis C 2015;J Hepatol,2015

3. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection;Afdhal;N Engl J Med,2014